FDA to review Kowa Pharmaceuticals’ NDA for glaucoma eye drop K-911

K-911 is being developed as a topical ophthalmic monotherapy formulated as a sterile solution. Credit: Gorodenkoff / Shutterstock.com.



  • FDA Kowa K-911